Urine Raman spectroscopy platform for non-invasive disease
This technology uses a laser-based technique called Raman spectroscopy to analyze urine samples and detect molecular patterns associated with specific diseases. Rather than looking for a single biomarker, it reads the entire molecular 'fingerprint' of the urine and runs that spectral data through a pipeline of machine learning and statistical tools to classify whether a patient has a particular condition. The system is trained on urine spectra from both healthy and diseased individuals, then validated to report how accurately it can distinguish between the two groups. The result is a non-invasive, urine-based diagnostic framework that could potentially identify multiple diseases from a single sample type.
What you could build
A laboratory diagnostic platform or clinical decision-support software that processes urine Raman spectra to screen for or characterize specific diseases, sold to hospital systems, clinical labs, or diagnostic instrument manufacturers as a workflow add-on or standalone assay kit.
Who in Virginia should care
Academic medical centers and health system networks in Virginia (e.g., UVA Health, VCU Health) and diagnostic device companies in the Northern Virginia/DC corridor would be plausible early partners or licensees.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- John L. Robertson, Ryan Senger
- Filed
- Patent pending — filed January 11, 2021
- Status
- Application
- Publication number
- US20210215610A1
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.